Hyderabad, 20 November 2026: Iron deficiency anaemia affects millions of people worldwide, especially in low- and middle-income countries, and access to affordable treatment remains challenging. In an important step to address this challenge, BE Biosol Private Limited, a wholly owned subsidiary of Biological E. Limited, has entered into an agreement with the Gates Foundation for the development and improve accessibility of Ferric Carboxymaltose (FCM) injection to multiple countries.

The Gates Foundation will support BE Biosol for scale-up and clinical development of the product for the target markets. BE Biosol will leverage its R&D capabilities and manufacturing infrastructure to support the programme. Commissioned in 2018, its manufacturing facility in Shamirpet, Telangana, has undergone multiple inspections and received approvals multiple times from leading regulatory agencies, including the USFDA, Infarmed (Portugal), the UK MHRA and Brazil's ANVISA.

The agreement is particularly strategic for BE Biosol as the US and European FCM markets approach a transition towards generic competition. By leveraging its manufacturing scale and its proprietary API technology, BE Biosol aims to establish a differentiated, cost-competitive offering and build a meaningful presence in these markets.

Commenting on the development, Narender Mantena, Managing Director of BE Biosol Private Limited, said: "Our collaboration with the Gates Foundation reaffirms our commitment to public health, which an important part of our legacy. It also reflects confidence in BE Biosol’s capabilities to develop and manufacture technologically demanding sterile formulations at competitive costs and scale. More broadly, this collaboration reinforces our strategy to establish BE Biosol as a globally competitive CDMO platform across complex biologics and pharmaceutical modalities "

About BE BioSol Private Limited

BE Biosol Private Limited is the CDMO arm of Biological E. Limited, a Hyderabad-based pharmaceutical and biologics company founded in 1953. Building on the Group's distinctive expertise and track record in vaccines, BE Biosol is developing a differentiated and globally competitive CDMO platform serving biopharmaceutical partners from development through commercialisation. Its focus areas include vaccines, monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), mRNA therapeutics and complex injectable products.

For further details, please contact:

Jaya Vellampalli, Corporate Communications

+91 8008011879 | jaya.vellampally@biologicale.com 

PR Sutra: Giri @ 9963445785